Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that inhibits the H+/K+-ATPase enzyme system in the gastric parietal cell, suppressing both basal and stimulated gastric acid secretion. Standard formulations include delayed-release tablets and IV powder for reconstitution.
## Primary Indications
* Erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
* Prophylaxis of stress-induced upper GI bleeding (clinical practice, though often off-label).
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg PO or IV daily for 8 weeks; may extend another 8 weeks if necessary.
* **Maintenance of Healing:** 40 mg PO daily.
* **Hypersecretory Conditions:** Starting dose 40 mg twice daily. Doses up to 240 mg/day have been used clinically; titrate based on acid output.
* **Stress Ulcer Prophylaxis:** Common protocol is 40 mg IV daily or twice daily (follow institution-specific guidelines).
## Pediatric Dosing
* **Erosive Esophagitis (≥5 years):**
* 15 kg to <40 kg: 20 mg PO daily for up to 8 weeks.
* ≥40 kg: 40 mg PO daily for up to 8 weeks.
* **Safety/Efficacy:** Use in patients <5 years is generally not recommended due to limited data.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment necessary.
* **Hepatic Impairment:** Use caution; may consider a maximum dose of 20 mg daily or every other day in severe impairment (Child-Pugh C).
## Contraindications
* Known hypersensitivity to pantoprazole or any substituted benzimidazole (e.g., omeprazole, lansoprazole).
* Hypersensitivity to any component of the formulation.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypomagnesemia, Vitamin B12 deficiency (with long-term use), acute interstitial nephritis, and increased risk of bone fractures (hip, wrist, spine) with high-dose/long-term therapy.
## Key Drug Interactions
* **pH-Dependent Drugs:** May decrease absorption of drugs requiring acidic gastric pH (e.g., atazanavir, ketoconazole, iron salts, mycophenolate mofetil).
* **Methotrexate:** PPIs may increase serum levels of methotrexate, potentially leading to toxicity (monitor closely in high-dose therapy).
* **CYP2C19 Inhibitors/Inducers:** Minimal clinical impact compared to other PPIs, but monitor for altered efficacy.
## Monitoring
* **Long-term:** Serum magnesium (if on therapy >1 year), Vitamin B12 levels (if on therapy >2-3 years).
* **General:** Monitor for signs of GI bleeding, changes in bowel habits (*C. diff* risk), or new-onset unexplained bone pain.
## Clinical Pearls
* **Administration:** Tablets should be swallowed whole; do not split, crush, or chew.
* **Tapering:** Long-term users may experience rebound hyperacidity upon sudden discontinuation; consider a gradual taper.
* **IV vs Oral:** Transition to oral therapy as soon as patient can tolerate oral intake and the clinical condition is stable.
* **PPI Stewardship:** Review the necessity of continued PPI use periodically; avoid long-term use unless indicated for Barrett's esophagus, chronic NSAID use with risk factors, or hypersecretory conditions.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical guidelines and local protocols vary. Always consult the latest package insert, clinical pharmacists, or institutional prescribing policies before initiating or adjusting medication dosages.
